ClinicalTrials.gg
CompletedNCT05104853Updated Mar 10, 2026

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

A Phase 1/2 interventional study of CNP-104 and Placebo in Primary Biliary Cholangitis, sponsored by COUR Pharmaceutical Development Company, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by COUR Pharmaceutical Development Company, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 17 under way, 7 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
36th of 65
42 · median 46
Started
2022
with 7 others
Phase 1/2
2 of 83
none open now
Registered
58th of 83
by date

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 36th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2022, is one of 2 in phase 1/2, and was the 58th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

Read the detailed description

Subjects ages 18-75 with primary biliary cholangitis will be screened up to 14 days prior to enrollment into the study. Screening will be completed to assess eligibility, obtain vital signs, collect laboratory samples and PD measurements, and to receive a FibroScan for liver fibrosis. Subjects will additionally complete an initial PBC-40 assessment and begin an Itch Diary, a questionnaire and scoring system to be completed by the patient every morning and evening through Day 120 and then monthly through end of study.

Subjects who meet all inclusion and no exclusion criteria after completing the screening visit will be enrolled in the study. Subjects will be randomized on Day 1 in a 1:1 ratio to receive either CNP-104 or Placebo (0.9% Sodium Chloride USP) by intravenous (IV) infusion. Subjects will be administered CNP-104 or Placebo on Day 1 and on Day 8. This study was originally designed with 2 cohorts, Cohort 1 comprised of 6 subjects randomized 1:1 to placebo or 4 mg/kg, and Cohort 2 comprised of up to 34 subjects randomized 1:1 to placebo or 8 mg/kg. Under Protocol Amendment 6 (v7.0), the remaining subjects for Cohort 2 (approximately 16) will be randomized 1:3:1 to placebo, 4 mg/kg, and 8 mg/kg respectively.

Subjects will remain in the clinic on Day 1 and Day 8 from the time of admission (prior to administration of CNP-104 or Placebo) through the final procedure conducted 4 hours post-dose that same day unless an infusion reaction, or other adverse event, requires an extended duration of monitoring. Subjects will be discharged if safety parameters are acceptable to the investigator.

Seven days after the second administration of CNP-104 or Placebo, subjects must return to the clinic for collection of safety labs, PD measurements, and assessment of AEs and medication changes.

Subjects will continue to be followed for 2 years to assess safety, pharmacodynamics, and immunogenicity during the Post-Dosing period.

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written and privacy language as per national regulations.
  2. Men and non-pregnant women, ages 18-75 years inclusive.
  3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors:

    1. Alkaline phosphatase > 1.5× for at least 6 months
    2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex])
    3. Liver findings consistent with PBC
  4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP > 1.5× ULN.
  5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator.
  6. Subjects with ALP > 1.5× ULN.
  7. Subjects with and ALT \< 5× ULN.
  8. Subjects with ≥ 10 g/dL.
  9. Subjects with total \< 2× ULN.
  10. Men and women of (WOCBP) must agree to practice a highly effective method of that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90.
  11. Female subjects who agree not to donate ova starting at initial screening and through Day 90.
  12. Male subjects who agree to not donate sperm starting at screening and through Day 90.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a Class B or Class C score.
  2. Subjects with concomitant liver diseases including chronic viral or C, hepatitis, PSC, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's syndrome.
  3. Subjects who have previously undergone liver transplantation.
  4. Subjects with decompensated liver disease as defined by the presence or history of any of the following:

    • MELD score > 15
    • Hepatic encephalopathy
    • Ascites
    • Hepatorenal syndrome or serum creatinine > 2 mg/dL
    • Total > 3.0 mg/dL
    • >1.8 unless on anticoagulation such as Coumadin
    • History of variceal hemorrhage
  5. Subjects with a history of cerebrovascular accident in the past 12 months.
  6. Subjects with history of myocardial infarction, as defined by any of the following criteria:

    • Development of pathological Q waves with or without symptoms
    • Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause
    • Pathological findings of a healed or healing myocardial
  7. Subjects with chronic kidney disease, as defined by estimated (eGFR) \< 60 mL/min/1.73 m2 for at least 3 months (per CKD EPI Equation - 2021).
  8. Subjects with uncontrolled diabetes, as defined by > 7%.
  9. Subjects who have used the following medications:

    • Methotrexate within 90 days of screening.
    • Immunotherapy drugs unless approved by the medical monitor.
  10. Subjects with a history of tuberculosis or positive PPD skin test.
  11. Subjects who have received administration of any (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to screening or are planning to receive any vaccination before Day 90.
  12. Subjects who have used systemic within 3 months prior to screening.
  13. Subjects with laboratory test results at screening or prior to study dosing that are outside the normal limits and considered by the Investigator to be .

    Note: This criterion does not apply to liver function tests. Additionally, clinically significant laboratory test results at screening that are related to the condition (PBC) are acceptable as long as all inclusion and no other exclusion criteria are met.

  14. Subjects with positive test results for hepatitis B surface antigen (HBsAg), virus (HCV) antibody, or (HIV) antigen/antibody as determined at screening.
  15. Subjects with a history of or currently active immune disorders other that PBC (including autoimmune disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
  16. Subjects with a history of or current active diseases requiring drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
  17. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator.
  18. Subjects with a complication or medical history of within past 5 years which, in the Investigator's opinion, makes the subject unsuitable for study participation.
  19. Subjects who, in the Investigator's opinion, will be unable to adhere to study procedures.
  20. Subjects who have received an therapy other than CNP-104 within 28 days or 5 half-lives, whichever is longer, prior to screening.
  21. Subjects with any condition which, in the Investigator's opinion, makes the subject unsuitable for study participation.
  22. Known sensitivity to any components of CNP-104.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    4 mg/Kg CNP-104

    200 mL intravenous infusion on Day 1 and Day 8: 4 mg/Kg CNP-104

    Drug: CNP-104

  • Experimental
    8 mg/Kg CNP-104

    200 mL intravenous infusion on Day 1 and Day 8: 8 mg/Kg CNP-104

    Drug: CNP-104

  • Placebo comparator
    Placebo

    200 mL intravenous infusion on Day 1 and Day 8: Placebo

    Drug: Placebo

Interventions

  • DrugCNP-104

    CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.

  • DrugPlacebo

    CNP-104 Placebo

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Frequency tables will be presented by treatment group for all AEs and SAEs by System Organ Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by treatment group for AEs leading to discontinuation from TP and study, by severity, and by causality. No formal statistical testing will be done

    Time frame: through Study Completion, an average of 720 Days

  2. Laboratory safety assessments (hematology, serum chemistry, coagulation panel, urinalysis).

    Frequency tables of each assessment abnormalities by grade and treatment will be presented. No formal statistical testing will be done.

    Time frame: through Study Completion, an average of 720 Days

  3. Serum Cytokines (TNF-α, IL-4, IL-6, IL-10, IL-1β, MCP-1, MIP-1α, IFN-γ)

    Frequency tables will be presented by treatment group. No formal statistical testing will be done

    Time frame: through CNP-Dosing Period, an average of 15 Days

Secondary outcomes

  1. To assess the change from baseline in Serum Alkaline Phosphatase (ALP) levels, for safety only

    Change from baseline in ALP levels at Day 60 and Day 720

    Time frame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days

  2. To assess the change from baseline in AMA

    Change from baseline in AMA between placebo and CNP-104 at Day 90 and Day 720

    Time frame: through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days

  3. To assess the change from baseline in liver fibrosis by FibroScan

    Change from baseline in liver fibrosis by FibroScan between placebo and CNP-104 at Day 90 and Day 720

    Time frame: through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days

  4. To assess the change from baseline in modified PBC-40 score

    Change from baseline in modified PBC-40 score between placebo and CNP-104 at Day 60 and Day 720

    Time frame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days

  5. To assess the change from baseline in Weekly Mean Itch Score

    Change from baseline in Weekly Mean Itch Score between placebo and CNP-104 at Day 60 and Day 720

    Time frame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 D

  6. To assess the change from baseline in liver enzymes (Albumin, Bilirubin (total and direct), ALT, AST, GGT)

    Change from baseline in liver enzymes at Days 60 and 720

    Time frame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days

  7. To assess the change in antigen specific CD4+ and CD8+ T cells

    Change from baseline in antigen specific CD4+ and CD8+ T at Days 60 and 720

    Time frame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days

07

Study locations

19 sites
  • Southern California Research Center
    Coronado, California 92118, United States
  • OM Research
    Lancaster, California 93534, United States
  • University of California Davis Health
    Sacramento, California 95817, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Yale School of Medicine
    New Haven, Connecticut 06520, United States
  • University of Florida - Hepatology Research
    Gainesville, Florida 32610, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Florida Research Institute
    Lakewood Rch, Florida 34211-4930, United States
  • GI PROS Research
    Naples, Florida 34102, United States
  • Cleveland Clinic - Florida
    Weston, Florida 33331, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Washington University School of Medicine in St. Louis
    St Louis, Missouri 63110, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
08

References and documents

Publications

  • Klatzkow H, Bhavsar-Burke I, Pearson M, Wentworth BJ. Primary Biliary Cholangitis in 2025: A New Frontier. Am J Gastroenterol. 2025 Dec 1;120(12):2746-2749. doi: 10.14309/ajg.0000000000003559. Epub 2025 May 29. No abstract available. PubMed 40439725 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jan 2026, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Nov 3, 2021
StartActual
Jan 25, 2022
Primary completionActual
Jan 30, 2026
CompletionActual
Jan 30, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05104853
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Jan 25, 2022
Primary completion
Jan 30, 2026
Completion
Jan 30, 2026
Last update
Mar 10, 2026

Study contacts

Christopher Bowlus, MD
principal investigator · UC Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion